FCPA & Anti-Corruption for the Life Sciences Industry

APRIL 14. 2021 (EDT) | VIRTUAL CONFERENCE | EARN CLE CREDITS

2021 GOVERNMENT SPEAKERS

David Last, Assistant Chief, FCPA Unit, Fraud Section, Criminal Division, U.S. Department of Justice

Robert I. Dodge, Assistant Director, FCPA Unit, U.S. Securities and Exchange Commission

Bernard J. Cooney, Assistant United States Attorney, U.S. Attorney’s Office, District of New Jersey

Check out some of our most popular sessions

• FCPA ENFORCEMENT IN THE LIFE SCIENCES ARENA: Emerging Liability Risks and New Enforcement Priorities Amid Covid-19

• SPECIAL INTERVIEW WITH NOVARTIS: Reflecting on the 2020 Settlement and a Reimagined Approach to Ethics & Compliance

• Digital Transformation for Anti-Corruption: Leveraging Data Analytics, Automation and Machine Learning to Prevent and Detect FCPA Violations

• How to Measure the Effectiveness of Your Compliance Program: Industry-Specific Considerations

Watch a Complimentary FCPA Life Science Webinar!

New FCPA & Anti-Corruption Compliance Red Flags for 2021: Biden Administration, Covid-19, and More on the Horizon

Nancy A. Grygiel, Senior Vice President & Chief Compliance Officer, Amgen Inc.

Gary DiBianco, Partner, Skadden, Arps, Slate, Meagher & Flom LLP

Michelle J. Shapiro, Partner, Arent Fox

www.AmericanConference.com/FCPA-Life-Sciences